19 August 2019
We are pleased to announce that Dr Gareth Blades has joined Amati as an analyst supporting the fund management team.
Prior to Amati, Gareth worked as an independent consultant supporting early stage, life science companies in their operational and strategic decision making. In 2016 he worked for the College of Medicine and Veterinary Medicine at the University of Edinburgh building and spinning-out therapeutic, med-tech, diagnostic and e-health companies. In 2015, Gareth worked in healthcare corporate finance at PharmaVentures in Oxford. During his time at PharmaVentures he delivered expert reports, business development, licensing and due diligence projects for international clients. Prior to this he worked for White Space Strategy in Oxford, a leading market analysis and strategy consultancy serving financial services, TMT, manufacturing, energy and public sector clients. Gareth has a DPhil in Systems Biology - Biochemistry from the University of Oxford, an MPhil in Micro and Nanotechnology Enterprise from the University of Cambridge and a first in Neuroscience from Cardiff University.
Gareth’s role at Amati will involve working with the fund managers in researching potential new investments, as well as carrying out ongoing monitoring of existing portfolio companies. Amati will benefit from his background in life sciences, providing greater insight to its coverage of the healthcare, pharmaceutical and biotechnology sectors. This expertise will prove particularly valuable to Amati’s due diligence process into investments for its AIM VCT, where the legislative emphasis on “knowledge based” companies is generating an active pipeline of early stage, life science companies. It is intended that Gareth’s future sector coverage will expand beyond his initial responsibilities, as he gains public market experience.